VKTX Q3'26 Earnings: EPS estimate is (1.06) USD

What happened

Viking Therapeutics is set to announce its Q3'26 results on October 28 after the market closes, at 4:00 PM ET. The revenue estimate is 0 USD and the earnings per share estimate is (1.06) USD.

Confirmed

Global impact / market context

A zero revenue estimate signals investors expect no product sales yet, so the loss per share is the main scorecard. A wider loss than forecast could raise questions about how long the company's cash can fund research and development.

Analyst inference

The company has reported losses in recent quarters, and the Q3'26 estimate of a (1.06) USD loss per share is narrower than the (1.10) USD loss reported in the earlier quarter. Estimates are projections, not reported results, so the actual figure may differ.

Analyst inference

What to watch

1. Watch for the actual Q3'26 revenue and earnings per share when Viking Therapeutics reports on October 28 after the market closes, and compare them with the 0 USD revenue and (1.06) USD loss estimates. Confirmed
2. Listen for any company comment on planned research spending and how existing cash will cover it, since a zero revenue estimate means operations depend on funds already raised or borrowed. Proposed
3. A larger-than-expected loss could prompt investors to reassess how long the company's cash lasts, potentially affecting its stock price and its ability to raise additional money. Analyst inference

Evidence

• Original source link unavailable